Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival rate of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-specific molecular information difficult. Here we have overcome this problem by applying blind source separation to a diverse collection of PDAC gene expression microarray data, including data from primary tumor, metastatic and normal samples. By digitally separating tumor, stromal and normal gene expression, we have identified and validated two tumor subtypes, including a 'basal-like' subtype that has worse outcome and is molecularly similar to basal tumors in bladder and breast cancers. Furthermore, we define 'normal' and 'activated' stromal subtypes, which are independently prognostic. Our results provide new insights into the molecular composition of PDAC, which may be used to tailor therapies or provide decision support in a clinical setting where the choice and timing of therapies are critical.
Rigorous sequencing studies have shown that few genetic alterations (occurring in KRAS, CDKN2A, SMAD4 and TP53) are prevalent in PDAC [1] [2] [3] , but these and other analyses of PDAC tumors are hampered by limited tumor cellularity and the presence of abundant stroma intermixed with normal endocrine and exocrine cells. Additionally, metastatic samples often include cell types from the host organ. Thus, PDAC tumors are complex mixtures in which malignant epithelial cells often represent a minority of the tissue compartment (Fig. 1a) . Illustrating this limitation, an important study of the exome and copy number in pancreatic cancer removed 43 of 142 patients because of low tumor cellularity affecting the sensitivity of mutation detection 1 . Although some studies use microdissection to improve tumor content [4] [5] [6] [7] , using microdissection for precision medicine approaches is not yet feasible. When considering the gene expression of bulk tumor samples, normal pancreas and PDAC tissues often cluster together, separate from cell lines, which are assumed to be purely neoplastic 8 .
Separating the molecular signatures of tissue compartments from measurements of bulk tumor samples belongs to the general class of problems called blind source separation. Previous studies have used chronic pancreatitis samples, which are often fibrotic, to control for the presence of desmoplastic stroma in tumor samples 9 . In prostate cancer, Stuart et al. have used pathology assessments of cell types to train models of gene expression signatures for tumor, stroma and normal tissue 10 . In a follow-up study, they used their learned gene lists for the in silico estimation of tissue components in a larger data set 11 . A similar approach has also been used to quantify stromal content across multiple data sets from The Cancer Genome Atlas (TCGA) 12 . Among source separation techniques, non-negative matrix factorization (NMF) is especially well suited for biological data because it constrains all sources to be positive in nature, reflecting the goal of identifying positive gene expression exemplars rather than pairwise differences between tissue types. Briefly, we define NMF as modeling the matrix X of expression for g genes and s samples, constituting the product of a matrix G of g gene weights for k factors and a matrix S of s sample weights for k factors. Alexandrov et al. have recently demonstrated that NMF is useful for a similar problem of identifying mutational signatures from the aggregate list of somatic mutations in human cancer samples 13, 14 . Similarly, Biton et al. have applied a related technique, independent component analysis, to examine gene expression in bladder cancer 15 .
Virtual microdissection identifies distinct tumorand stroma-specific subtypes of pancreatic ductal adenocarcinoma
In this study, we have overcome the challenges of bulk tumor analysis, wherein signal is averaged out between normal, tumor and stromal compartments, by using NMF to perform virtual microdissection of primary and metastatic PDAC samples. This has allowed us to identify tumor-specific and stroma-specific subtypes with prognostic and biological relevance. In addition, by focusing on tumor-autonomous gene expression, we found that within-patient tumor heterogeneity between primary and metastatic sites was unexpectedly low.
RESULTS

Virtual microdissection of PDAC
We used NMF to analyze gene expression in a collection of microarray data from 145 primary and 61 metastatic PDAC tumors, 17 cell lines, and 46 pancreas and 88 distant site adjacent normal samples generated using Agilent human whole-genome 4x44K DNA microarrays (106 primary tumors were previously used in a separate bulk analysis of gene expression (Gene Expression Omnibus (GEO), GSE21501; ref. 16 ). 
A r t i c l e s
To validate our findings, we performed RNA sequencing (RNA-seq) on 15 primary tumors, 37 pancreatic cancer patient-derived xenografts (PDXs), 3 PDAC cell lines and 6 cancer-associated fibroblast (CAF) lines derived from deidentified samples collected from patients with pancreatic cancer (Supplementary Data Set) . The histology of all available samples was reviewed by a single pathologist blinded to sample identity (K.E.V.). The demographic and clinical characteristics of the patients with primary tumors available in our cohorts are summarized in Table 1 .
NMF distinguishes normal and tumor compartments
A key obstacle in the analysis of tumor gene expression data, particularly in PDAC, is the removal of confounding gene expression data for normal tissue and stroma collected at local and distant organ sites. Examples of histology for samples with tumor, stroma and normal tissue are shown in Supplementary Figure 1 . We used NMF to identify gene expression patterns that we attributed to normal pancreas, liver, lung, muscle and immune tissues. Expression of exemplar genes from these factors (genes with distinctly large weights in a single column of G) as well as factor weights for the samples (rows of S) showed excellent agreement with known tissue labels (Fig. 1b,c and Supplementary Fig. 2 ).
Investigation of the exemplar genes from these factors further confirmed the role of these factors as confounding normal tissue. For example, using the Kolmogorov-Smirnov test, the top weighted genes from the liver factor showed significant (P < 1 × 10 −10 ) enrichment for the MSigDB term SU_LIVER (Supplementary Table 1) , and the gene with the highest weighting, FGB (encoding fibrinogen β) (Supplementary Table 2 ), was specifically expressed in normal human liver tissue. In addition to factors corresponding to normal tissue from distant organs, we found two factors that were exclusive to pancreas tissue but were differentiated from each other by their respective gene lists. One factor described endocrine function, including expression of GCG and INS (encoding glucagon and insulin) (Supplementary Table 2) , whereas the other factor described exocrine function, including expression of digestive enzyme genes such as PNLIP (encoding pancreatic lipase) (Supplementary Table 2 ). This unsupervised discovery of two molecularly distinct yet highly colocalized factors related to normal pancreatic function represents an important proof of concept in the use of NMF to identify new features without predefined knowledge of expression.
To validate our expression signatures for normal tissue, all available samples were reviewed by a single pathologist (K.E.V.) to independently assess the tumor, stromal and normal cellularity. We found that many factor weights were correlated or anticorrelated with tumor cellularity (Supplementary Fig. 3 ). Among normal and metastatic liver samples, for example, weights for tumor-specific factors were correlated with tumor cellularity, whereas the weight for the factor corresponding to normal liver was inversely related to the tumor content of a sample (Fig. 1d) . These findings support our hypothesis that the factor weights obtained from NMF are quantitatively indicative of underlying sample composition.
Identification of stroma-specific subtypes
Stroma is particularly important in PDAC. According to pathology assessments, the stroma was varied ( Supplementary Fig. 1c-e) and comprised on average 48% of our primary tumor samples (s.d. = 30%). Our analysis identified two factors that described gene expression from the stroma (Fig. 2) , which were distinctly different from the factors for normal tissue shown in Figure 1 . Consensus clustering on exemplar genes from these two stromal factors divided the tumor samples into two stromal subtypes, which we classified as 'normal' and 'activated' (Fig. 2a) . Patients whose samples belonged to the activated stromal subtype had a worse median survival time of 15 months and 1-year survival rate of 60% when compared to patients whose samples belonged to the normal stromal subtype (median survival time of 24 months and 1-year survival rate of 82%; Fig. 2b ). The expression signatures for both subtypes were notably absent in PDAC cell lines (Fig. 2c) , which exhibited a distinct mitotic expression signature associated with mitotic checkpoints and DNA replication (Supplementary Table 1 ) 17 .
The fact that the cell lines did not express the genes from these stromal factors and that many metastatic samples expressed them at low levels ( Supplementary Fig. 4 ) suggests that the genes from these factors are not expressed by the tumor epithelium. To further validate the stromal origin of these gene expression signatures, we isolated six CAF lines from primary tumors ( Supplementary  Fig. 5 ) and found that they robustly overexpressed our hypothesized stromal signature genes in comparison to the PDAC tumor cell lines, which had no expression of the stromal signature genes (Fig. 2c) .
The vast majority of collagen gene expression was attributable to stromal compartments, with the lone exception being COL17A1, which was highly expressed in tumors. Normal stroma was characterized by relatively high expression of known markers for pancreatic stellate cells, ACTA2, VIM and DES (encoding smooth muscle actin, vimentin and desmin). Stellate cells 
A r t i c l e s
have been shown to promote cancer cell survival in vitro 18 but also may restrain PDAC in mouse models 19, 20 . Targeting desmoplastic stroma by Hedgehog pathway inhibition has been shown to both accelerate the development of disease 21 and enhance the delivery of chemotherapy 22 . In patients, the ratio of the area stained for smooth muscle actin to the area stained for collagen has been shown to be predictive of poor outcomes 23 . We found that activated stroma was characterized by a more diverse set of genes associated with macrophages, such as the integrin ITGAM and the chemokine ligands CCL13 and CCL18. Activated stroma also expressed other genes 
Tumor subtype npg that point to its role in tumor promotion, including the secreted protein SPARC, the Wnt family members WNT2 and WNT5A, MMP9 (gelatinase B) and MMP11 (stromelysin 3). The presence of FAP (encoding fibroblast activation protein), which has previously been related to worse prognosis, in the gene signature for activated stroma suggests that an activated fibroblast state may be partially responsible for the poor outcomes for patients with this stromal subtype 24 . This led us to hypothesize that the normal stromal factor might describe a 'good' version of stroma, whereas the activated stromal factor might describe the activated inflammatory stromal response that has been seen in previous studies to be responsible for disease progression [25] [26] [27] . Our factor analysis supports a complex, multigene model of stroma in PDAC, which may explain why singlegene analysis has yielded mixed results.
Identification of tumor-specific subtypes
We found that two tumor-specific factors, independent of normal and stromal factors, defined 'classical' and 'basal-like' subtypes of PDAC. When our samples were split into the two tumor subtypes (Fig. 3a) , patients with tumors in the basal-like subtype had an overall significantly (P = 0.007) worse median survival time of 11 months and 1-year survival rate of 44% in comparison to a survival time of 19 months and 1-year survival rate of 70% for patients with tumors in the classical subtype (Fig. 3b) . All cell lines assayed in this study 
npg
A r t i c l e s (P < 0.001), as well as a majority of the metastatic samples (P = 0.002), were classified as basal-like, suggesting that cell line models represent only one subset of PDAC. These subtypes as well as their prognostic value were independently validated in the recently published International Cancer Genome Consortium (ICGC) PDAC microarray data set (Fig. 3c,d ) 28 . The expression of genes from the basal-like factor, including ones encoding laminins and keratins, was also consistent with basal subtypes previously defined in bladder [29] [30] [31] and breast 32 cancers (Fig. 3e-h) . Interestingly, genes from our basal-like subtype reproduced subtype calls (P < 0.001) in breast cancer, had prognostic value in breast cancer samples (P < 0.001) and reproduced previous subtype calls in bladder cancer (TCGA bladder cancer) 29 (P < 0.001). Given these promising results, we developed a single-sample cross-platform classifier of the basallike subtype that was trained on our microarray data, the TCGA bladder cancer data and the breast cancer data from Prat et al. 33 , with a cross-validation accuracy of 93%, and was able to classify TCGA breast cancer data with 92% accuracy during external validation ( Supplementary Fig. 6, Supplementary Table 3 and Supplementary Note).
Potential subtypes of PDAC have previously been described by Collisson et al. 5 . We used the published exemplar genes for the 'exocrine-like' , 'classical' and 'quasimesenchymal' subtypes to cluster normal pancreas, cell lines and primary PDAC tumors from our cohort (Supplementary Fig. 7a) . The three previous classifications were also observed in our data but did not hold prognostic power either by cluster label or by supervised classification with Prediction Analysis for Microarrays (PAM) 34 (Supplementary Fig. 7b) . Basal-like and classical tumors were found in both the normal and activated stromal subtypes (Fig. 4a) . Differential prognosis among tumor and stromal subtypes was cumulative, as tumors from the classical subtype with the normal stromal subtype (n = 24) had the lowest hazard ratio of 0.39 (95% confidence interval (CI) = 0.21-0.73), whereas tumors from the basal-like subtype with the activated stromal subtype (n = 26) had the highest hazard ratio of 2.28 (95% CI = 1.34-3.87) (Fig. 4b) . In a multivariate Cox regression model that included tumor subtypes, stromal subtypes and clinical variables (sex, ancestry, T stage, N stage, margin status, adjuvant therapy, histological grade and age), both classifications were independently associated with survival (stroma subtypes, P = 0.037; tumor subtypes, P = 0.003).
Although tumors in the basal-like subtype had worse prognosis independent from race and stroma (Fig. 4b,e) , patients with basal-like tumors showed a strong trend toward better response to adjuvant therapy (P = 0.072; Fig. 4c,d ). Among patients with the basal-like subtype, adjuvant therapy provided a hazard ratio of 0.38 (95% CI = 0.14-1.09), whereas, in patients with tumors from the classical subtype, adjuvant therapy was associated with a hazard ratio of only 0.76 (95% CI = 0.40-1.43). In our cohort, there was no association of most clinical variables (ancestry, sex, T stage, N stage, differentiation or tumor cellularity) with survival, although positive nodal status trended toward significant association with survival and positive margin status was significantly (P = 0.026) associated with worse survival ( Table 1) . Two-way associations of all subtype calls with clinical and pathological information from our cohort of patients with PDAC is shown in Table 2 . We found no association of tumor or stromal subtype with standard clinical or pathological variables, with the notable exception of mucinous features.
Tumor-specific subtypes in patient-derived xenografts To assess the tumor or stromal specificity of our signatures, we performed RNA-seq on a group of 37 PDX tumors. PDX tumors are composed of human tumor cells surrounded by mouse stroma (Supplementary Fig. 8 ) 35 . Genes from both of our tumor signatures were expressed as human transcripts, whereas genes from both of our stromal signatures were expressed as mouse transcripts (Fig. 2d and  Supplementary Fig. 9a) . Furthermore, we found that PDX RNA-seq expression divided PDXs into tumors with classical and basal-like groupings (Supplementary Fig. 9b ) that both predominantly expressed an activated stromal signature (Fig. 2d) . We found that, whereas the tumor-specific subtype was not predictive of graft success (Fig. 5a) , patient-derived tumors with the activated stromal subtype had significantly higher graft success rates than those with the normal stromal subtype or low amounts of stroma (Fig. 5b) (P = 0.019). Tumors in the basal-like subtype also exhibited faster growth rates than tumors in the classical subtype (P = 0.032), as measured by the length of time that tumors took to grow to 200 mm 3 (TT200; Fig. 5c,d) , a previously used metric for PDX growth 36 . Retrospective analysis of patients who had matched PDX tumors found that shorter TT200 was associated with unfavorable recurrence-free survival (P = 0.035; Fig. 5e ), suggesting that PDX tumor growth rate may reflect patient biology. We also measured both mouse-and human-specific expression of the genes from Collisson et al. in our PDX models. We found that, while genes from the classical subtype were expressed by human cells in PDXs, quasimesenchymal genes were expressed by a mixture of human and mouse cells and exocrine-like genes were infrequently expressed (Supplementary Fig. 7c ). This finding supports our hypothesis that, whereas the classical subtype is a bona fide group, the quasimesenchymal subtype is partially driven by non-tumor contributions from stroma and the exocrine-like subtype corresponds to normal pancreas. 37, 38 , and these mutations have been shown to be associated with differential outcome in some clinical studies. Because PDX tumors are enriched for human-specific tumor cells, we evaluated KRAS codon mutations in our PDX cohort using manually curated RNA-seq data. Although the overall frequency of KRAS codon mutations was similar to that in a recent study of PDAC 7 , we noted that the KRAS mutation encoding p.Gly12Asp was significantly over-represented in our basal-like subtype, whereas the mutation encoding p.Gly12Val was only found in the classical subtype (P = 0.030; Fig. 5f ). Furthermore, we found an over-representation of KRAS mutations encoding p.Gly12Val in African Americans (P < 0.001; Fig. 5g) . In contrast to basal-like breast cancers, which occur most frequently in African-American women and have a worse prognosis 39 , the tumors from African-American patients in our cohort tended to be mainly of the classical subtype (13 versus 2 tumors). We found that, as in other cancers, the prognosis in African Americans was worse after adjusting for tumor subtype (P = 0.017; Fig. 4e) . African-American patients with tumors of the classical subtype had a median survival time of 13 months in comparison to Caucasian patients with tumors from the classical subtype who had a median survival time of 19 months.
KRAS codon mutations, tumor-specific subtypes and ancestry
Studies of KRAS codon mutations have demonstrated that mutations of different codons may have distinct functions
Other commonly mutated genes and altered pathways in PDAC Previously, loss of SMAD4 has been shown to promote tumor growth 40, 41 . We found that, as in previous PDX studies of PDAC, loss of SMAD4 was associated with graft success in PDX models 42 (P = 0.044; Fig. 5h and Supplementary Fig. 10 ). Furthermore, in our PDX cohort, we found that SMAD4 expression was significantly higher in classical than in basal-like PDX tumors (P = 0.015; Fig. 5i) , consistent with the observation that SMAD4 loss confers a more aggressive phenotype.
Using mutation, genomic subtype 3 and gene expression 28 data from the publically available ICGC cohort in which we recapitulated our subtypes and their effects on prognosis, we evaluated significantly mutated genes and pathways in PDAC, including ones recently identified through whole-exome sequencing of microdissected primary PDAC tumors [1] [2] [3] 7 . We found no significant associations between our expression subtypes and these mutationally altered pathways, including the transforming growth factor (TGF)-β, RB, Notch, CTNNB1, SWI/SNF chromatin-remodeling and DNA repair pathways (Supplementary Fig. 11 ). Furthermore, we found no overlap between our subtypes and recently identified genomic subtypes or response groups for platinum therapy 3 . Consistent with this analysis, a recent comprehensive study of somatic mutations in long-term survivors of PDAC suggested that somatic mutations alone will not be sufficient to explain clinical outcome 43 .
Given the overlap of our classical subtype with that of Collisson et al. 5 , it was not surprising to find that our classical subtype was also enriched for genes associated with GATA6 overexpression 44 (Fig. 4a  and Supplementary Fig. 12a ). GATA6 has been found to promote APOC3  LOC388503  CYP8B1  CFHR2  HAMP  ITIH1  C9  F9  FGB  SERPINC1  BAAT  C8A  HRG  FGA  ORM16  ORM2  HPR  FABP1  IGFBP1  SAA1  CYP2E1  ARG1  C4BPA  CPB2  FGG  ALDOB  FGL1  GC  TM4SF4  TTR  APOH  ITIH4  MAT1A  CABP7  CEACAM6  DMBT1  SFTPA1  SFTPC  CPA1  CPB1  ELA3B  PNLIP  CTRB1  GCG  INS  XIST  REG1A  RPS4Y1  OLFM4 The correlation of samples within the same patient is higher when using the tumor-specific genes than when using the most differentially expressed genes. (d) The correlation of samples originating in the same organ is higher when using the most differentially expressed genes than when using the tumor-specific genes. (e) Clustering of multiple samples from two patients using the 50 most differentially expressed genes divides samples by organ. Genes expressed highly in lung and liver tissues are noted with brackets. Clustering of the same samples using the 50 genes specific to tumor subtypes separates samples by patient. Brackets note genes whose expression differentiates the two patients. A diagram of sampled locations for these patients (indicated by concentric circles) illustrates how samples simultaneously exhibit both patient-and organ-specific gene expression.
npg epithelial cell differentiation 44, 45 . This result prompted us to perform a more detailed analysis of histological markers of differentiation in our samples, and we found that samples with greater than 10% extracellular mucin, a marker of differentiation, comprised mostly tumors of the classical subtype (88.5%; n = 23) in comparison to only 11.5% (n = 3) of tumors from the basal-like subtype (P = 0.042; Table 2 and Supplementary Fig. 13 ). Consistent with the increased presence of extracellular mucin, our classical subtype was enriched for genes upregulated in mucinous ovarian cancer ('Wamaunyokoli ovarian cancer grade 1 2 up' classification 46 ; Supplementary Fig. 12b) . Interestingly, our basal-like subtype was enriched for genes related to KRAS activation and STK11 loss in a mouse model of lung cancer where STK11-deficient tumors demonstrated shorter latency and more frequent metastasis 47 ( Supplementary Fig. 12c) . We identified one sample with STK11 inactivation in the ICGC data set; this sample was in the basal-like subtype (Supplementary Fig. 11) . Notably, our subtypes were not associated with other known signaling pathways in PDAC, including the Fanconi anemia 48 , DNA repair, chromatin-remodeling 49 , β-catenin 50 , RB, ARF and G1 (ref. 51) pathways (Fig. 4a) . However, genes from all of these pathways, except for β-catenin signaling, were considerably differentially expressed in cell lines in comparison to patient-derived tumors, suggesting that gene expression in cell lines may be a deceptive representation of the expression in most tumors.
Low within-patient heterogeneity in tumor-specific genes
We expect that only a subset of genes is relevant to the question of within-and between-patient heterogeneity in PDAC. Many methods exist to preselect genes for supervised analysis 52 , but selection of the most differentially expressed genes is a common preprocessing step during unsupervised analysis 53 . When clustering matched samples of metastatic and primary lesions using the 50 most differentially expressed genes among all matched samples, the samples separated primarily by organ site instead of by patient (Fig. 6a,c) . In contrast, when considering 25 top-ranked exemplar genes each from the basallike and classical factors, samples from the same patient clustered closer together with the clustering less dependent on organ site (Fig. 6b,d ). This trend was further illustrated in a focused analysis of two patients (Fig. 6) , whose tumor samples appeared to be patient specific when considering our tumor subtype gene list but clustered by tumor site when considering differentially expressed genes. Overall, we found that our tumor subtype gene list showed higher similarity (mean Pearson's ρ = 0.53) between all other samples from the same patient than did the differentially expressed gene list (ρ = 0.32; t test, P < 0.001). Furthermore, our tumor subtype gene list produced much lower similarity among all other samples from the same organ site across different patients (ρ = 0.04) than the differentially expressed gene list (ρ = 0.34; P < 0.001). This observed similarity of tumor gene expression among tumors in the same patient suggests overall high between-patient tumor heterogeneity and low heterogeneity between primary and metastatic sites. However, we did observe examples of within-patient heterogeneity between metastatic sites. For example, lung metastases, even those from patients with basal-like tumors in other locations, clustered exclusively with tumors from the classical subtype, suggesting that some within-patient heterogeneity may exist among metastatic sites and supporting the previously reported divergent patterns of metastases in PDAC 54 .
DISCUSSION
Our study represents the largest investigation of primary and metastatic PDAC gene expression thus far. We have used purity-independent subtyping (PurISt) to identify new prognostic subtypes of PDAC that may have been obscured previously by confounding normal and stromal tissues. Our identification of normal-, tumor-and stroma-specific gene expression signatures is supported by both the overlap of these signatures with previously identified gene lists and their expression in appropriate tissue types. Our tumor subtypes are further supported by their relationship to previously identified basal tumor subtypes in breast and bladder cancers and their prognostic relevance in external cohorts. Our findings of two different stromal subtypes may help explain the differential effects of stroma previously seen in preclinical models. Tumor-and stroma-specific gene expression classified PDAC into four distinct subtypes with prognostic relevance. The orthogonal nature of the tumor-and stroma-specific subtypes suggests an important interplay between tumors in patients that will need to be taken into account as stroma-and immune-modulating therapies are studied. In our cohort, patients with basal-like tumors appeared to derive more benefit from adjuvant therapy. Whether the basal-like and classical subtypes may be associated with response to specific therapies will need to be studied further as more effective therapies become available. One challenge will be defining preclinical model systems that recapitulate these subtypes, as our results suggest that traditional cell lines are lacking in the classical subtype. Although we demonstrate that PDX models recapitulate tumor-specific subtypes, these models alone may not be sufficient because of either the lack of human stroma or over-representation of the activated stromal subtype among the tumors that are successfully grafted. Thus, more detailed characterization of genetically engineered mouse models of PDAC will be needed to determine which models best reflect both our tumor-and stroma-specific subtypes.
Recent exome sequencing studies have confirmed commonly mutated genes in PDAC but have not uncovered mutations that clearly confer differences in survival [1] [2] [3] 7 . In fact, exome sequencing of a cohort of very long-term survivors of PDAC 43 found no differences in somatic mutations to explain the improved biology of tumors from these rare patients in comparison with the majority of patients with PDAC, suggesting that examining somatic mutations alone may not be sufficient to understand the biological and clinical differences in PDAC tumors. Furthermore, exome sequencing studies and studies of microdissected samples are limited to the tumor compartment and overlook the stromal compartment, which has been shown to be biologically critical in PDAC, with both tumor-promoting and tumor-inhibiting effects. Our results suggest that RNA-determined subtypes may better capture the molecular landscape of PDAC and better reflect patient outcome. We hypothesize that our RNA subtypes may reflect the broad effect of somatic mutations while also capturing the importance of the neoplastic stroma.
These results provide new insights into the molecular composition of PDAC, which may be used for precision medicine. Furthermore, knowledge of these subtypes and their prognostic value may provide decision support in a clinical setting, where the choice and timing of therapies are critical.
URLs. International Cancer Genome Consortium (ICGC) data portal, https://dcc.icgc.org/; The Cancer Genome Atlas (TCGA) data portal, https://tcga-data.nci.nih.gov/tcga/.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Decomposition by factors and gene ranking. For all analyses in this manuscript, we used k = 14 as the number of factors. Unsupervised NMF was performed on a gene-by-sample matrix X first with 20 randomly initialized instances of NMF using the MATLAB (MathWorks, R2013a) multiplicative update NMF solver for 10 steps. The pair with the lowest residual solution from these 20 instances was then used to seed NMF of X to convergence with the alternating least-squares solver. The result was a matrix of gene loadings, G, and a matrix of sample loadings, S. G and S were then scaled such that the mean of each column of G was 1 to facilitate crossfactor comparisons.
For each of the k factors, a set of distinct exemplar genes for the ith factor was established by ranking genes in descending order of the difference between the loading value in the ith column of matrix G and the largest loading value not in the ith column of matrix G.
Two hundred iterations of fivefold resampling, training on a partition of approximately 80% of the samples, were performed to achieve stable NMF results. For each of these 200 data partitions, unsupervised NMF was performed, and the genes that appeared ranked in the top 50 of any factor together were recorded in a gene-by-gene consensus matrix. This gene factor co-occurrence consensus matrix was then used as the basis of a hierarchical clustering operation using correlation as a distance metric and an appropriate cutoff so as to yield k gene clusters. These k gene clusters were used to create a seed matrix G 0 such that the ith column of G 0 contained 0.01 for all genes except those in gene cluster i, for which the values were set to 1. G 0 was then used to seed a final NMF with the multiplicative update solver to completion.
Gene set analysis was performed on the ranked list of genes for each factor with all sets available from MSigDB 55 v3. ) ) and immortalized human pancreatic duct-derived (HPNE) cells were described previously 56 . All cell lines were authenticated via short-tandem repeat (STR) profiling (Genetica), and all cell lines were mycoplasma negative by indirect staining. For survival analysis, only data from patients with localized resected tumors were used. RNA-seq was performed on an additional 15 primary tumors, 37 pancreatic cancer PDXs, 3 cell lines (HuPT3 plus 2 derived from PDXs) and 6 CAF lines derived from deidentified samples from patients with pancreatic cancer.
PDXs and derived cells. Fresh deidentified tumor samples from patients with PDAC were obtained under protocols approved by the UNC IRB. All patient tissues were stained with hematoxylin and eosin to confirm histology. The tumors were implanted subcutaneously into the flanks of 6-to 8-week-old female NSG NOD/SCID or nu/nu mice and subsequently passaged into other mice under protocols approved by the UNC Institutional Animal Care and Use Committee.
Cell lines were derived from PDXs as follows. At the time of passage, a section of the tumor was cut into approximately 3-mm pieces and rinsed with PBS containing penicillin and streptomycin. The tissue was minced with a gentleMACS Dissociator (Miltenyi Biotec) and incubated for 30 min in Collagenase/Dispase (Roche, 11097113001) solution. After incubation, mincing was repeated, the dissociation medium was removed and the tissue was resuspended in DMEM/F12 medium supplemented with 5 ng/ml epidermal growth factor (EGF), 10 µg/ml insulin (Life Technologies, 11330-032, PHG0311 and 12585-014, respectively), 10% FBS and 1× penicillin and streptomycin and seeded onto treated tissue culture plates. Once culture was established, differential trypsinization was used to remove fibroblasts, and cells were seeded on gelatin-coated glass coverslips for immunofluorescence confirmation. Epithelial tumor cells were confirmed on the basis of their expression of human cytokeratin 18 or 19 and EpCAM (using ab133302 and ab76539 (Abcam) and 324209 (BioLegend) antibodies, respectively).
Primary CAF cell lines derived from tumors of patients with PDAC were isolated using the outgrowth method as follows 57 . Fresh tumor was minced into pieces no larger than 1 mm 3 and cultured with DMEM/Ham's F12 (1:1) medium supplemented with 10% FBS. Immunofluorescence was used to confirm the presence of CAFs as defined by staining for smooth muscle actin α (SMAα; Santa Cruz Biotechnology, sc-32251) and a mesenchymal marker, vimentin (Cell Signaling Technology, 5741), as well as the absence of staining for an epithelial marker, EpCAM (BioLegend, 324209).
Statistical analysis. For all analyses, the sample size was limited to all appropriate cases with full data; no imputation was performed to estimate missing clinical information. Disease-specific survival or recurrence-free survival was analyzed using the Kaplan-Meier product-limit method, and the significance of clinicopathological or subtype variables was measured by Cox proportional hazards regression. Multivariate associations with survival were also performed using the Cox proportional hazards regression method. When more than two survival cohorts were compared, the log-rank test was used to assess global differences in survival. Fisher's exact test was used to analyze associations between two categorical variables. For continuous variables, for example, stain intensity and factor weight, unpaired two-tailed two-sample t tests were performed under the assumption of equal variance. Box-and-whisker plots show the median, quartiles and range of continuous data to demonstrate the variability of data and the degree of normality. Unless otherwise mentioned, sample-to-sample and gene-to-gene similarities were measured by correlation on the basis of log 2 -transformed gene expression after normalizing the expression for each gene to have a mean of 0 and variance of 1. Unless otherwise noted, clustering was performed via consensus clustering of row-normalized gene expression. Consensus clustering consisted of 1,000 iterations of k-means clustering, with 50% feature hold-out at each iteration, followed by hierarchical clustering of the consensus matrix with average linkage.
Microarray data. All RNA isolation and hybridization were performed at UNC on Agilent human whole-genome 4x44K microarrays (Agilent Technologies). RNA was extracted from macrodissected snap-frozen tumor samples using AllPrep kits (Qiagen) and quantified using Nanodrop spectrophotometry (Thermo Scientific). RNA quality was assessed with the use of the Bioanalyzer 2100 chip (Agilent Technologies). RNA was selected for hybridization using RNA integrity number and by inspection of 18S and 28S ribosomal RNA. Similar RNA quality was selected across samples. RNA (1 µg) was used as a template for cDNA preparations. cDNA was labeled with Cy5-dUTP and a reference control (Stratagene) was labeled with Cy3-dUTP using the Agilent Low-RNA Input Linear Amplification kit (Agilent Technologies) and hybridized overnight at 65 °C to Agilent 4x44K whole-human genome arrays. Arrays were washed and scanned using an Agilent scanner (Agilent Technologies). 
